Diabetic Kidney Disease Market Rising Valuation to Reach US$ 4.21 Billion by 2031

The growth of the
global diabetic kidney disease market is driven by the increasing incidence of
diabetes and rising geriatric population. According to the International
Diabetes Federation, the number of people with diabetes is projected to rise
from 415 million in 2015 to 642 million by 2040. Aging populations are at a
higher risk of developing diabetic kidney disease as renal function declines
with age. Furthermore, advances in treatment and rising awareness about
diabetic kidney disease diagnosis and management are expected to offer
lucrative growth opportunities for market players in the near future.

Request for a
sample of this research report @

Key Market
Trends:

The demand for
combination therapy for diabetic kidney disease is growing rapidly. Combination
therapy involves the administration of two or more drugs that work via different
mechanisms. For instance, the combination of SGLT2 inhibitors with
renin–angiotensin system inhibitors has shown promising results. SGLT2
inhibitors reduces kidney function decline in patients with diabetic kidney
disease. Development of novel drugs and rising adoption of digital health
platforms for diabetic kidney disease monitoring are some key trends expected
to shape the market over the forecast period.

Diabetic
Kidney Disease Market Report Coverage

Market
Opportunities

The drug class
segment of the diabetic kidney disease market is expected to be dominated by
the ACE inhibitors subsegment, accounting for over 35% market share by 2031.
ACE inhibitors help reduce protein in the urine and slow the progression of
kidney disease in people with diabetes. Drugs like Ramipril, Lisinopril and
Benazepril which belong to the ACE inhibitors class are widely prescribed for
the treatment of diabetic kidney disease.

Oral route of
administration is anticipated to hold the largest share of the diabetic kidney
disease market during the forecast period. The oral route is the most preferred
and convenient method of drug administration for chronic conditions like
diabetic kidney disease. Over 60% of drugs prescribed for treatment of diabetic
kidney disease such as ACE inhibitors, SGLT-2 inhibitors etc. are administered
via the oral route owing to ease of use and improved patient compliance.

Immediate
Delivery is Available | Get Full Report Access@

Key Market
Takeaways

The global
diabetic kidney disease market is anticipated to witness a CAGR of 4.8% during
the forecast period 2024-2031, driven by the growing prevalence of diabetes and
rising incidence of kidney disease associated with uncontrolled diabetes.

On the basis of
drug class, the ACE inhibitors subsegment is expected to hold a dominant
Position, accounting for over 35% market share by 2031 owing to their efficacy
in slowing the progression of kidney damage caused by diabetes.

By route of
administration, the oral route is expected to hold a dominant position over the
forecast period, with over 60% share due to benefits like convenience of use
and improved patient compliance with oral drugs.

Regionally, North
America is expected to dominate the global diabetic kidney disease market owing
to high prevalence of diabetes in the US and Canada along with growing
awareness about diabetes care.

Competitor
Insights:

GSK

Sanofi

Novartis

Pfizer

Boehringer
Ingelheim

Recent
Developments

In June 2023, the
US Food and Drug Administration (FDA) approved Janssen’s SGLT2
inhibitorInvokana (canagliflozin) for the treatment of DKD. This marked the
first FDA approval of an SGLT2 inhibitor specifically for slowing the
progression of kidney disease in patients with type 2 diabetes. Data from the
Phase 3 CREDENCE trial showed canagliflozin reduced the composite renal outcome
of end-stage kidney disease, doubling of serum creatinine, and renal or
cardiovascular death by 30% compared to placebo in patients with diabetic
nephropathy. The approval provides another treatment option beyond ACE
inhibitors or ARBs for patients needing additional renal protection. Janssen is
expected to see strong demand and uptake for Invokana as the only approved
SGLT2 inhibitor for diabetic kidney disease.

In July, the FDA
approved Travere Therapeutics’ Sparsentan for the treatment of IgA nephropathy,
a rare kidney disorder caused due to deposition of immunoglobulin A in the
kidneys. Sparsentan, a dual angiotensin receptor neprilysin inhibitor, showed
statistically significant reductions in proteinuria compared to irbesartan, an
angiotensin receptor blocker, in the phase 3 PROTECT study. While not indicated
for DKD, off-label use of sparsentan is expected to benefit DKD patients with
proteinuria.

Customize this
study as per your requirement @

Transform your Strategy with Exclusive Trending Reports:

Batten
Disease Treatment Market – Global Industry Insights, Trends, Outlook, and
Opportunity Analysis

Equine
Healthcare Market – Global Industry Insights, Trends, Outlook, and
Opportunity Analysis

Ambulatory
Services Market – Global Industry Insights, Trends, Outlook, and
Opportunity Analysis

The global companion
animal vaccine market is estimated to be valued at US$ 3.35 Billion in 2023
and is expected to exhibit a CAGR of 6.8% during the forecast period
(2023-2030).

About Us:
Coherent Market Insights leads into data and analytics, audience measurement,
consumer behaviors, and market trend analysis. From shorter dispatch to
in-depth insights, CMI has exceled in offering research, analytics, and
consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools
and custom-made research services, we empower businesses to move in the
direction of growth. We are multifunctional in our work scope and have 450+
seasoned consultants, analysts, and researchers across 26+ industries spread
out in 32+ countries.

Contact Us:

Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights

Phone:

US: + 12524771362

UK: +442039578553

AUS: +61-2-4786-0457

India: +91-848-285-0837